TY  - JOUR
AU  - Petrović, Nina
AU  - Nakashidze, Irina
AU  - Nedeljković, Milica
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9555
AB  - Breast cancer (BC) is a leading cause of death among women with malignant diseases. The selection of adequate therapies for highly invasive and metastatic BCs still represents a major challenge. Novel combinatorial therapeutic approaches are urgently required to enhance the efficiency of BC treatment. Recently, microRNAs (miRNAs) emerged as key regulators of the complex mechanisms that govern BC therapeutic resistance and susceptibility. In the present review we aim to critically examine how miRNAs influence BC response to therapies, or how to use miRNAs as a basis for new therapeutic approaches. We summarized recent findings in this rapidly evolving field, emphasizing the challenges still ahead for the successful implementation of miRNAs into BC treatment while providing insights for future BC management. The goal of this review was to propose miRNAs, that might simultaneously improve the efficacy of all four therapies that are the backbone of current BC management (radio-, chemo-, targeted, and hormone therapy). Among the fifty-nine described miRNAs, miR-21 and miR-16 emerged as the most promising, closely followed by miR-205, miR-451, miR-182, and miRNAs from the let-7 family. miR-21 inhibition might be the best choice for future improvement of invasive BC treatment. New therapeutic strategies of miRNA-based agents alongside current standard treatment modalities could greatly benefit BC patients. This review represents a guideline on how to navigate this elaborate puzzle. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
T2  - Journal of Mammary Gland Biology and Neoplasia
T1  - Breast Cancer Response to Therapy: Can microRNAs Lead the Way?
VL  - 26
IS  - 2
SP  - 157
EP  - 178
DO  - 10.1007/s10911-021-09478-3
ER  - 

@article{
author = "Petrović, Nina and Nakashidze, Irina and Nedeljković, Milica",
year = "2021",
abstract = "Breast cancer (BC) is a leading cause of death among women with malignant diseases. The selection of adequate therapies for highly invasive and metastatic BCs still represents a major challenge. Novel combinatorial therapeutic approaches are urgently required to enhance the efficiency of BC treatment. Recently, microRNAs (miRNAs) emerged as key regulators of the complex mechanisms that govern BC therapeutic resistance and susceptibility. In the present review we aim to critically examine how miRNAs influence BC response to therapies, or how to use miRNAs as a basis for new therapeutic approaches. We summarized recent findings in this rapidly evolving field, emphasizing the challenges still ahead for the successful implementation of miRNAs into BC treatment while providing insights for future BC management. The goal of this review was to propose miRNAs, that might simultaneously improve the efficacy of all four therapies that are the backbone of current BC management (radio-, chemo-, targeted, and hormone therapy). Among the fifty-nine described miRNAs, miR-21 and miR-16 emerged as the most promising, closely followed by miR-205, miR-451, miR-182, and miRNAs from the let-7 family. miR-21 inhibition might be the best choice for future improvement of invasive BC treatment. New therapeutic strategies of miRNA-based agents alongside current standard treatment modalities could greatly benefit BC patients. This review represents a guideline on how to navigate this elaborate puzzle. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.",
journal = "Journal of Mammary Gland Biology and Neoplasia",
title = "Breast Cancer Response to Therapy: Can microRNAs Lead the Way?",
volume = "26",
number = "2",
pages = "157-178",
doi = "10.1007/s10911-021-09478-3"
}

Petrović, N., Nakashidze, I.,& Nedeljković, M.. (2021). Breast Cancer Response to Therapy: Can microRNAs Lead the Way?. in Journal of Mammary Gland Biology and Neoplasia, 26(2), 157-178.
https://doi.org/10.1007/s10911-021-09478-3

Petrović N, Nakashidze I, Nedeljković M. Breast Cancer Response to Therapy: Can microRNAs Lead the Way?. in Journal of Mammary Gland Biology and Neoplasia. 2021;26(2):157-178.
doi:10.1007/s10911-021-09478-3 .

Petrović, Nina, Nakashidze, Irina, Nedeljković, Milica, "Breast Cancer Response to Therapy: Can microRNAs Lead the Way?" in Journal of Mammary Gland Biology and Neoplasia, 26, no. 2 (2021):157-178,
https://doi.org/10.1007/s10911-021-09478-3 . .

TY  - JOUR
AU  - Koridze, Marina
AU  - Baratashvili, Davit
AU  - Khukhunaishvili, Rusudan
AU  - Nakashidze, Irina
AU  - Petrović, Nina
AU  - Nagervadze, Marina
AU  - Zosidze, Nato
AU  - Tskvitinidze, Sophiko
AU  - Kotrikadze, Nanuli
AU  - Ahmad, Sarfraz
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1952
AB  - Breast cancer is one of the most frequent neoplastic diseases within the female population worldwide. Hormonal imbalance and the ABO system group antigens are among the numerous risk-factors which provoke the development of breast benign and malignant tumors. Here, we have investigated the following sex-steroid hormones: estradiol (E2), progesterone (P), testosterone (T)), non-sex hormones (thyroxin (fT4), thyroid-stimulating hormone (TSH) and prolactin (PRL), and the distribution of the ABO system phenotypic groups in the menopausal and postmenopausal women with breast tumors (benign, malignant). Enzyme-linked immunosorbent assay (ELISA) was used for quantitative determination of hormones. The immune-serological methods were used for investigation of the ABO system phenotypic groups. Our present investigations in menopausal and postmenopausal women with breast tumors have revealed significantly higher expression of sex-steroid hormone estradiol, but decreased progesterone, and also significantly increased testosterone levels. Thyroid gland revealed hypofunction, which confirms the decrease of thyroxin, and increase of prolactin and TSH in the blood. According to our findings, carriers of A(II) phenotypic groups showed high risk for breast tumors development in women during both stages, menopausal and postmenopausal.
T2  - Indian Journal of Experimental Biology
T1  - Hormonal status and distribution of the ABO system phenotypic groups in menopausal and postmenopausal women with breast tumors
VL  - 56
IS  - 2
SP  - 93
EP  - 100
UR  - https://hdl.handle.net/21.15107/rcub_vinar_1952
ER  - 

@article{
author = "Koridze, Marina and Baratashvili, Davit and Khukhunaishvili, Rusudan and Nakashidze, Irina and Petrović, Nina and Nagervadze, Marina and Zosidze, Nato and Tskvitinidze, Sophiko and Kotrikadze, Nanuli and Ahmad, Sarfraz",
year = "2018",
abstract = "Breast cancer is one of the most frequent neoplastic diseases within the female population worldwide. Hormonal imbalance and the ABO system group antigens are among the numerous risk-factors which provoke the development of breast benign and malignant tumors. Here, we have investigated the following sex-steroid hormones: estradiol (E2), progesterone (P), testosterone (T)), non-sex hormones (thyroxin (fT4), thyroid-stimulating hormone (TSH) and prolactin (PRL), and the distribution of the ABO system phenotypic groups in the menopausal and postmenopausal women with breast tumors (benign, malignant). Enzyme-linked immunosorbent assay (ELISA) was used for quantitative determination of hormones. The immune-serological methods were used for investigation of the ABO system phenotypic groups. Our present investigations in menopausal and postmenopausal women with breast tumors have revealed significantly higher expression of sex-steroid hormone estradiol, but decreased progesterone, and also significantly increased testosterone levels. Thyroid gland revealed hypofunction, which confirms the decrease of thyroxin, and increase of prolactin and TSH in the blood. According to our findings, carriers of A(II) phenotypic groups showed high risk for breast tumors development in women during both stages, menopausal and postmenopausal.",
journal = "Indian Journal of Experimental Biology",
title = "Hormonal status and distribution of the ABO system phenotypic groups in menopausal and postmenopausal women with breast tumors",
volume = "56",
number = "2",
pages = "93-100",
url = "https://hdl.handle.net/21.15107/rcub_vinar_1952"
}

Koridze, M., Baratashvili, D., Khukhunaishvili, R., Nakashidze, I., Petrović, N., Nagervadze, M., Zosidze, N., Tskvitinidze, S., Kotrikadze, N.,& Ahmad, S.. (2018). Hormonal status and distribution of the ABO system phenotypic groups in menopausal and postmenopausal women with breast tumors. in Indian Journal of Experimental Biology, 56(2), 93-100.
https://hdl.handle.net/21.15107/rcub_vinar_1952

Koridze M, Baratashvili D, Khukhunaishvili R, Nakashidze I, Petrović N, Nagervadze M, Zosidze N, Tskvitinidze S, Kotrikadze N, Ahmad S. Hormonal status and distribution of the ABO system phenotypic groups in menopausal and postmenopausal women with breast tumors. in Indian Journal of Experimental Biology. 2018;56(2):93-100.
https://hdl.handle.net/21.15107/rcub_vinar_1952 .

Koridze, Marina, Baratashvili, Davit, Khukhunaishvili, Rusudan, Nakashidze, Irina, Petrović, Nina, Nagervadze, Marina, Zosidze, Nato, Tskvitinidze, Sophiko, Kotrikadze, Nanuli, Ahmad, Sarfraz, "Hormonal status and distribution of the ABO system phenotypic groups in menopausal and postmenopausal women with breast tumors" in Indian Journal of Experimental Biology, 56, no. 2 (2018):93-100,
https://hdl.handle.net/21.15107/rcub_vinar_1952 .

TY  - JOUR
AU  - Petrović, Nina
AU  - Sami, Ahmad
AU  - Martinović, Jelena
AU  - Zarić, Marina
AU  - Nakashidze, Irina
AU  - Lukić, Silvana
AU  - Jovanović-Ćupić, Snežana P.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1805
AB  - Background: Breast carcinomas (BC) belong to a heterogeneous group of malignant diseases. Correct categorization of BC based on molecular biomarkers has a very important role in deciding the proper course of therapy for each patient. It has been already shown that the decrease of TIMP metalloproteinase inhibitor 3 (TIMP-3) together with overexpression of microRNA-21 (miR-21) might be involved in the process of BC invasion. This is the first study that examined relationship among miR-21, TIMP-3 mRNA and TIPM-3 protein levels in BC groups formed according to invasiveness. Methods: In this study, we used 46 breast cancer samples. Estrogen and progesterone receptor (ER, PR) protein levels were evaluated by immunohistochemistry (IHC) method. TIMP-3 mRNA expression was examined by two-step real-time quantitative PCR (qRT-PCR). Western blot analysis was performed for 16 samples. Results: Statistically significant differences in TIMP-3 expression levels between invasive groups were discovered in ER positive (ER+) (p = 0.015), Her-2 negative (p = 0.026) subgroups, and patients without lymph-node metastasis (p = 0.039). Interestingly, significant positive correlation was detected between miR-21 and TIMP-3 mRNA levels (P LT 0.001, p = 0.949) in the group of in situ tumors. TIMP-3 mRNA expression levels highly negatively correlated with levels of miR-21 in PR + invasive BCs (p = 0.007, p = -0.641). TIMP-3 protein levels negatively correlated with miR-21 levels in pure invasive BCs. Conclusion: These data suggest that signaling pathways involved in formation and progression of BCs in groups formed according to invasiveness might be different. Our findings propose that TIMP-3 mRNA expression levels could be significant prognostic parameter, but within specific BC subtypes.
T2  - Pathology Research and Practice
T1  - TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC
VL  - 213
IS  - 10
SP  - 1264
EP  - 1270
DO  - 10.1016/j.prp.2017.08.012
ER  - 

@article{
author = "Petrović, Nina and Sami, Ahmad and Martinović, Jelena and Zarić, Marina and Nakashidze, Irina and Lukić, Silvana and Jovanović-Ćupić, Snežana P.",
year = "2017",
abstract = "Background: Breast carcinomas (BC) belong to a heterogeneous group of malignant diseases. Correct categorization of BC based on molecular biomarkers has a very important role in deciding the proper course of therapy for each patient. It has been already shown that the decrease of TIMP metalloproteinase inhibitor 3 (TIMP-3) together with overexpression of microRNA-21 (miR-21) might be involved in the process of BC invasion. This is the first study that examined relationship among miR-21, TIMP-3 mRNA and TIPM-3 protein levels in BC groups formed according to invasiveness. Methods: In this study, we used 46 breast cancer samples. Estrogen and progesterone receptor (ER, PR) protein levels were evaluated by immunohistochemistry (IHC) method. TIMP-3 mRNA expression was examined by two-step real-time quantitative PCR (qRT-PCR). Western blot analysis was performed for 16 samples. Results: Statistically significant differences in TIMP-3 expression levels between invasive groups were discovered in ER positive (ER+) (p = 0.015), Her-2 negative (p = 0.026) subgroups, and patients without lymph-node metastasis (p = 0.039). Interestingly, significant positive correlation was detected between miR-21 and TIMP-3 mRNA levels (P LT 0.001, p = 0.949) in the group of in situ tumors. TIMP-3 mRNA expression levels highly negatively correlated with levels of miR-21 in PR + invasive BCs (p = 0.007, p = -0.641). TIMP-3 protein levels negatively correlated with miR-21 levels in pure invasive BCs. Conclusion: These data suggest that signaling pathways involved in formation and progression of BCs in groups formed according to invasiveness might be different. Our findings propose that TIMP-3 mRNA expression levels could be significant prognostic parameter, but within specific BC subtypes.",
journal = "Pathology Research and Practice",
title = "TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC",
volume = "213",
number = "10",
pages = "1264-1270",
doi = "10.1016/j.prp.2017.08.012"
}

Petrović, N., Sami, A., Martinović, J., Zarić, M., Nakashidze, I., Lukić, S.,& Jovanović-Ćupić, S. P.. (2017). TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. in Pathology Research and Practice, 213(10), 1264-1270.
https://doi.org/10.1016/j.prp.2017.08.012

Petrović N, Sami A, Martinović J, Zarić M, Nakashidze I, Lukić S, Jovanović-Ćupić SP. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. in Pathology Research and Practice. 2017;213(10):1264-1270.
doi:10.1016/j.prp.2017.08.012 .

Petrović, Nina, Sami, Ahmad, Martinović, Jelena, Zarić, Marina, Nakashidze, Irina, Lukić, Silvana, Jovanović-Ćupić, Snežana P., "TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC" in Pathology Research and Practice, 213, no. 10 (2017):1264-1270,
https://doi.org/10.1016/j.prp.2017.08.012 . .